Matt Pauls, Chair and CEO of Savara, expressed optimism about the data supporting MOLBREEVI’s efficacy in improving pulmonary gas exchange and clinical symptoms of aPAP. Savara has requested a ...

Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA marks an important milestone for the Company and the ...

Matt Pauls, Chair and CEO of Savara, expressed optimism about the data supporting MOLBREEVI’s efficacy in improving pulmonary gas exchange and clinical symptoms of aPAP. Savara has requested a ...

If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year. The Company remains on track to file the Marketing Authorization Application for MOLBREEVI ...

Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company focused on developing novel therapies for rare respiratory diseases, is approaching a critical juncture in its journey to bring its lead ...

As the company completes its rolling Biologics License Application (BLA) submission for Molbreevi, investors and analysts are closely watching the potential first-in-class treatment for autoimmune ...

“MOLBREEVI has the potential to be the first and only approved therapy for aPAP in the U.S. and Europe and could redefine the standard of care for the disease. If granted Priority ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, alongside key updates on its MOLBREEVI program, which aims to address ...

Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI * as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP ...